95 patents
Utility
Crystalline Solid Forms of N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, Processes for Making, and Methods of Use
30 Nov 23
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Filed: 2 Aug 23
Utility
Heterocyclic Adenosine Receptor Antagonists
30 Nov 23
Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein.
Sunghoon Ma, Yong Wang, Wei Xu
Filed: 25 May 23
Utility
Compounds for the Treatment of Kinase-Dependent Disorders
23 Nov 23
Lynne Canne Bannen, Minna Bui, Faming Jiang, Yong Wang, Wei Xu
Filed: 13 Jun 23
Utility
CD47 Binding Agents and Uses Thereof
9 Nov 23
The present disclosure provides CD47 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.
Bryan GLASER, Bonnie HAMMER, Seema KANTAK
Filed: 3 Aug 21
Utility
Amh-competitive Antagonist Antibody
2 Nov 23
The present invention relates to a competitive antagonist antibody that specifically binds to AMHR-II, said antibody comprising (a) a heavy chain wherein the variable domain comprises a H-CDR1 having a sequence set forth as SEQ ID NO: 3; a H-CDR2 having a sequence set forth as SEQ ID NO: 4; and a H-CDR3 having a sequence set forth as SEQ ID NO: 5; and (b) a light chain wherein the variable domain comprises at least a CDR selected from the group consisting of a L-CDR1 having a sequence set forth as SEQ ID NO: 8, a L-CDR2 having a sequence set forth as SEQ ID NO: 9; and a L-CDR3 having a sequence set forth as SEQ ID NO: 10.
Jean-François PROST, Olivier DUBREUIL, Jean-Marc BARRET, Stéphane DEGOVE
Filed: 23 Oct 20
Utility
Method of Treating Cancer
5 Oct 23
This invention is directed to the treatment of cancer, particularly solid tumors, using cabozantinib in combination with an immune checkpoint inhibitor or an anti-cancer vaccine and in predicting responses to such cancer treatments.
Christopher Del Nagro, Jason Wall, Evelyn Wang, Chih-Jian Lih
Filed: 20 Aug 21
Utility
PD-L1 Binding Agents and Uses Thereof
28 Sep 23
The present disclosure provides PD-L1 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.
Bryan GLASER, Bonnie HAMMER, Seema KANTAK
Filed: 3 Aug 21
Utility
Liquid Dosage Forms to Treat Cancer
28 Sep 23
This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
Khalid Shah, Gisela Schwab, Steven Lacy
Filed: 28 Oct 22
Utility
Combinations for the Treatment of Cancer
28 Sep 23
The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1.
Gisela Schwab, Christian Scheffold, Colin Chong, Ssucheng Jeff Hsu, Peter Lamb, Peiwen Yu
Filed: 29 Jul 21
Utility
Method of Treating Cancer
28 Sep 23
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
David Smith, Maha Hussain
Filed: 21 Feb 23
Utility
Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
19 Sep 23
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Filed: 25 Mar 21
Utility
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
22 Aug 23
The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Khalid Shah
Filed: 9 Feb 22
Utility
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
15 Aug 23
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Filed: 29 Oct 20
Utility
Heterocyclic adenosine receptor antagonists
8 Aug 23
Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein.
Sunghoon Ma, Yong Wang, Wei Xu
Filed: 15 Mar 21
Utility
Compounds for the treatment of kinase-dependent disorders
25 Jul 23
Lynne Canne Bannen, Minna Bui, Faming Jiang, Yong Wang, Wei Xu
Filed: 25 Jan 19
Utility
Method of Treating Cancer and Bone Cancer Pain
18 May 23
This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone.
Gisela Schwab, Dana T. Aftab
Filed: 13 Oct 22
Utility
Compounds and Methods of Use
18 May 23
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.
Lynne Bannen, Wei Xu, Yong Wang, Andrew Raub, Benjamin Spangler, Justin Salvant, Kin Tso, Faming Jiang
Filed: 23 Feb 21
Utility
Method of treating cancer
28 Mar 23
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
David Smith, Maha Hussain
Filed: 18 Jun 20
Utility
MEK inhibitors and methods of their use
7 Mar 23
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof.
Naing Aay, Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Joerg Bussenius, Simona Costanzo, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Anagha Abhijit Joshi, Abigail R. Kennedy, Angie Inyoung Kim, Elena S. Koltun, Jean-Claire Limun Manalo, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang
Filed: 20 Apr 20
Utility
Salt Forms of a Kinase Inhibitor
16 Feb 23
Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
Filed: 12 Dec 19